Related Experiment Videos
-Prevention of respiratory syncytial virus infection-
1Service d'urgence et de réanimation pédiatrique, hôpital Edouard-Herriot, Lyon, France.
Insights
Respiratory syncytial virus (RSV) causes severe infant respiratory illness. While new vaccines and passive immunizations show promise, safe and effective prevention for all infants remains a critical challenge.
Area of Science:
- Virology
- Immunology
- Pediatrics
Context:
- Respiratory syncytial virus (RSV) causes significant annual respiratory disease in infants.
- Past vaccination attempts led to enhanced disease severity, necessitating new approaches.
- Maternal antibodies and infant tolerance are key considerations for current vaccine development.
Purpose:
- To review the current landscape of respiratory syncytial virus (RSV) prevention strategies.
- To evaluate the progress and challenges in developing safe and effective RSV vaccines and immunotherapies.
- To highlight ongoing research into passive and local immunization methods.
Summary:
- RSV prevention has long been sought, but early vaccines caused increased disease severity.
- New vaccine candidates show promise, but efficacy with maternal antibodies and infant tolerance require further study.
- Intravenous immunoglobulins are effective for high-risk children, and intranasal monoclonal antibodies are under investigation.
Impact:
- Advances in RSV prevention could significantly reduce infant morbidity and mortality.
- Successful vaccine and immunotherapy development will address a major public health concern.
- Improved prevention strategies are crucial for protecting vulnerable infant populations from severe respiratory illness.
Abstract:
Respiratory syncytial virus (RSV) is responsible for annual outbreaks of severe respiratory disease among infants. Its prevention has been considered for many years but the first vaccination trials resulted in diseases of increased severity. New vaccines are in progress with promising results, although their efficacy in the presence of maternal antibodies, and their tolerance in very young babies, remain to be demonstrated. Concerning passive immunization, intravenous anti-RSV immunoglobulins have been successfully tested in children at risk of severe bronchiolitis; however this prophylaxis is not applicable to healthy children. The use of local immunization with intranasal monoclonal antibodies is under study. While waiting for a safe and efficient immunization against RSV, prevention of nosocomial infections by cohorting and handwashing is recommended.